Back to search

University of Birmingham

Inhibition of the platelet glycoprotein VI receptor as a potential treatment for acute coronary syndromes

Abstract

dc:description.abstract

Aspirin and a P2Y12 inhibitor, such as ticagrelor, are routine treatments for myocardial infarction. However, these drugs are not always sufficient for heavy coronary thrombus burden during ST-elevation myocardial infarction (STEMI). More potent antiplatelet drugs (glycoprotein IIb/IIIa inhibitors) may help in this setting but are limited by excessive bleeding. As glycoprotein VI (GPVI) plays major roles in thrombosis, this thesis aimed to investigate whether a novel platelet GPVI inhibitor, glenzocimab (Acticor Biotech), provides additional antithrombotic effects when combined with aspirin and ticagrelor. Glenzocimab showed an amplified antiplatelet effect on collagen and atherosclerotic plaque-induced platelet aggregation without showing off-target effects on platelet activation mediated by non-GPVI agonists. Glenzocimab and eptifibatide (a glycoprotein IIb/IIIa antagonist) both exhibited similar inhibitory effects on collagen- and atherosclerotic plaque-induced platelet aggregation when used in combination with aspirin and ticagrelor. Glenzocimab also reduced fibrin-stimulated platelet aggregation more than aspirin and ticagrelor. Glenzocimab provided additional antiplatelet effects on platelet aggregation and adhesion and thrombus formation in blood sampled from patients with acute coronary syndromes treated with aspirin and ticagrelor. Glenzocimab blocked platelet procoagulant activity and reduced tissue factor-mediated peak thrombin generation. Glenzocimab did not affect early phases of coagulation (initiation, formation, and strength), which were greatly affected by eptifibatide, but it exerted some effects on clot lysis (late phases of coagulation) as assessed by ROTEM. This is the first work to show that the addition of a novel GPVI inhibitor, glenzocimab, to aspirin and ticagrelor provides greater inhibition of multiple critical mechanisms of arterial thrombosis. This is a promising strategy for the further development of treatment for STEMI due to the minimal role of GPVI in haemostasis.

Degree

thesis:*
Name dc:type.qualificationname
d_ph
Level dc:type.qualificationlevel
d_ph
Grantor dc:publisher.institution
University of Birmingham
Year dc:date.issued
2021

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Alenazy, Fawaz Obaidullah M.

Subjects

dc:subject × 1

Rights

Language dc:language.dcterms_iso639_2
eng

Chain of custody

source
Harvested from
University of Birmingham
Base URL
etheses.bham.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Alenazy, Fawaz Obaidullah M.. Inhibition of the platelet glycoprotein VI receptor as a potential treatment for acute coronary syndromes. d_ph thesis, University of Birmingham, 2021.